Tunicamycin inhibits progression of glioma cells through downregulation of the MEG‑3‑regulated wnt/β‑catenin signaling pathway

Li,Xin; Xue,Lei; Peng,Qin

doi:10.3892/ol.2018.8416

Tunicamycin inhibits progression of glioma cells through downregulation of the MEG‑3‑regulated wnt/β‑catenin signaling pathway

Authors:
- Xin Li
- Lei Xue
- Qin Peng
View Affiliations

Affiliations: Department of Neurosurgery, Jinshazhou Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510000, P.R. China, Clinical Skills Training Center, Guangzhou Medical University, Guangzhou, Guangdong 510182, P.R. China, Department of Orthopedics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510000, P.R. China
Published online on: April 3, 2018 https://doi.org/10.3892/ol.2018.8416
Pages: 8470-8476
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is derived from the oncogenic transformation of brain and spinal cord glial cells, and is one of the most common primary brain tumors. Tunicamycin (TUN) can significantly inhibit glioma growth and aggressiveness by promoting apoptosis in glioma cells. The purpose of the present study was to investigate the effects of TUN on growth of glioma cells and examine the TUN‑mediated signaling pathway. The inhibitory effects of TUN on apoptosis, growth, aggressiveness and cell cycle arrest of glioma tumor cells were determined by western blotting, reverse transcription‑ quantitative polymerase chain reaction, apoptotic assays and immunofluorescence. The results demonstrated that treatment with TUN suppressed growth, migration and invasion of glioma carcinoma cells. In addition, TUN treatment induced apoptosis of glioma cells through downregulation of Bcl‑2 and P53 expression levels. Findings also indicated that TUN suppressed proliferation and arrested the glioma cells in the S phase of the cell cycle. Further analysis of the mechanisms of TUN demonstrated that TUN treatment upregulated the expression levels of maternally expressed gene (MEG)‑3, wnt and β‑catenin in glioma cells. Furthermore, knockdown of MEG‑3 expression reversed the TUN‑decreased wnt/β‑catenin signaling pathway, which subsequently also reversed the TUN‑inhibited growth and aggressiveness of glioma cells. In conclusion, the findings in the present study indicated that TUN treatment inhibited growth and aggressiveness through MEG‑3‑mediated wnt/β‑catenin signaling, suggesting that TUN may be an efficient anticancer agent for the treatment of glioma.

View Figures

View References

1	Swanson KD, Lok E and Wong ET: An overview of alternating electric fields therapy (NovoTTF Therapy) for the treatment of malignant glioma. Curr Neurol Neurosci Rep. 16:82016. View Article : Google Scholar : PubMed/NCBI
2	Kumar A, Ahuja A, Ali J and Baboota S: Curcumin-loaded lipid nanocarrier for improving bioavailability, stability and cytotoxicity against malignant glioma cells. Drug Deliv. 23:214–229. 2016. View Article : Google Scholar : PubMed/NCBI
3	Wang K, Kievit FM, Jeon M, Silber JR, Ellenbogen RG and Zhang M: Nanoparticle-mediated target delivery of TRAIL as gene therapy for glioblastoma. Adv Healthc Mater. 4:2719–2726. 2015. View Article : Google Scholar : PubMed/NCBI
4	Hariri OR, Quadri SA, Farr S, Gupta R, Bieber AJ, Dyurgerova A, Corsino C, Miulli D and Siddiqi J: Third ventricular glioblastoma multiforme: Case report and literature review. J Neurol Surg Rep. 76:e227–e232. 2015. View Article : Google Scholar : PubMed/NCBI
5	Delfino KR, Serao NV, Southey BR and Rodriguez-Zas SL: Therapy-, gender- and race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival. Cancer Genomics Proteomics. 8:173–183. 2011.PubMed/NCBI
6	Lin N, Yan W, Gao K, Wang Y, Zhang J and You Y: Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: A multi-institutional analysis of 941 cases. PLoS One. 9:e948712014. View Article : Google Scholar : PubMed/NCBI
7	Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T and Sakai T: Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res. 65:6364–6370. 2005. View Article : Google Scholar : PubMed/NCBI
8	Miyake H, Hara I, Arakawa S and Kamidono S: Stress protein GRP78 prevents apoptosis induced by calcium ionophore, ionomycin, but not by glycosylation inhibitor, tunicamycin, in human prostate cancer cells. J Cell Biochem. 77:396–408. 2000. View Article : Google Scholar : PubMed/NCBI
9	de Freitas Junior JC, Bdu Silva R, de Souza WF, de Araújo WM, Abdelhay ES and Morgado-Díaz JA: Inhibition of N-linked glycosylation by tunicamycin induces E-cadherin-mediated cell-cell adhesion and inhibits cell proliferation in undifferentiated human colon cancer cells. Cancer Chemother Pharmacol. 68:227–238. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kim SH, Shin HY, Kim YS, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ and Lee SJ: Tunicamycin induces paraptosis potentiated by inhibition of BRAFV600E in FRO anaplastic thyroid carcinoma cells. Anticancer Res. 34:4857–4868. 2014.PubMed/NCBI
11	Xing Y, Ge Y, Liu C, Zhang X, Jiang J and Wei Y: ER stress inducer tunicamycin suppresses the self-renewal of glioma-initiating cell partly through inhibiting Sox2 translation. Oncotarget. 7:36395–36406. 2016. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Mesti T and Ocvirk J: Malignant gliomas: Old and new systemic treatment approaches. Radiol Oncol. 50:129–138. 2016. View Article : Google Scholar : PubMed/NCBI
14	Kunz M, Nachbichler SB, Ertl L, Fesl G, Egensperger R, Niyazi M, Schmid I, Tonn JC, Peraud A and Kreth FW: Early treatment of complex located pediatric low-grade gliomas using iodine-125 brachytherapy alone or in combination with microsurgery. Cancer Med. 5:442–453. 2016. View Article : Google Scholar : PubMed/NCBI
15	Nami B, Donmez H and Kocak N: Tunicamycin-induced endoplasmic reticulum stress reduces in vitro subpopulation and invasion of CD44+/CD24-phenotype breast cancer stem cells. Exp Toxicol Pathol. 68:419–426. 2016. View Article : Google Scholar : PubMed/NCBI
16	von dem Knesebeck A, Felsberg J, Waha A, Hartmann W, Scheffler B, Glas M, Hammes J, Mikeska T, Yan PS, Endl E, et al: RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas. Neoplasia. 14:526–534. 2012. View Article : Google Scholar : PubMed/NCBI
17	Johnson GG, White MC and Grimaldi M: Stressed to death: Targeting endoplasmic reticulum stress response induced apoptosis in gliomas. Curr Pharm Des. 17:284–292. 2011. View Article : Google Scholar : PubMed/NCBI
18	Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, Son MJ, Song HS, Shin HJ, Lee DS, et al: Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep. 16:33–39. 2006.PubMed/NCBI
19	Davis MI, Pragani R, Fox JT, Shen M, Parmar K, Gaudiano EF, Liu L, Tanega C, McGee L, Hall MD, et al: Small molecule inhibition of the Ubiquitin-specific protease USP2 accelerates cyclin D1 degradation and leads to cell cycle arrest in colorectal cancer and mantle cell lymphoma models. J Biol Chem. 291:24628–24640. 2016. View Article : Google Scholar : PubMed/NCBI
20	Li J, Zhou D, Wang Z, Tan L, Zhou Y and Sheng X: Reversal effect of 5-aza-2-deoxycytidine on the maternally expressed gene 3 promoter hypermethylation and its inhibitory effect on the proliferation of epithelial ovarian cancer cells. Zhonghua Zhong Liu Za Zhi. 37:324–329. 2015.(In Chinese). PubMed/NCBI
21	Yan-Hua L, Xiang-Lei L, Hong L and Jian-Jun W: Long noncoding ribonucleic acids maternally expressed gene 3 inhibits lung cancer tumor progression through downregulation of MYC. Indian J Cancer. 52 Suppl 3:E190–E193. 2015. View Article : Google Scholar : PubMed/NCBI
22	Sareddy GR, Challa S, Panigrahi M and Babu PP: Wnt/beta-catenin/Tcf signaling pathway activation in malignant progression of rat gliomas induced by transplacental N-ethyl-N-nitrosourea exposure. Neurochem Res. 34:1278–1288. 2009. View Article : Google Scholar : PubMed/NCBI
23	Wu W, Tian Y, Wan H, Song Y, Li J and Zhang L: The expressions of Wnt/β-catenin pathway-related components in brainstem gliomas. Can J Neurol Sci. 40:355–360. 2013. View Article : Google Scholar : PubMed/NCBI
24	Lu P, Wang Y, Liu X, Wang H, Zhang X, Wang K, Wang Q and Hu R: Malignant gliomas induce and exploit astrocytic mesenchymal-like transition by activating canonical Wnt/β-catenin signaling. Med Oncol. 33:662016. View Article : Google Scholar : PubMed/NCBI